Search

Your search keyword '"Novartis AG -- Management"' showing total 320 results
Start Over Descriptor "Novartis AG -- Management"
320 results on '"Novartis AG -- Management"'

1. Hospital Clinico San Carlos Researcher Updates Knowledge of Multiple Sclerosis (Beyond lines of treatment: embracing early high-efficacy disease-modifying treatments for multiple sclerosis management)

Subjects
Company business management, Multiple sclerosis -- Drug therapy, Diseases -- Drug therapy -- Spain -- Switzerland, Physical fitness, Pharmaceutical industry, Novartis AG -- Management
Abstract

2024 NOV 9 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on multiple sclerosis. According to news reporting out [...]

Published
2024

2. Novartis employs creative deal structure to establish Borealis Biosciences - divests legacy Chinook site, invests to form new company and engages in R&D collaboration

Subjects
Novartis AG -- Management, Versant Ventures -- Management, Drug discovery, Venture capital companies, Kidney diseases, Pharmaceutical industry, Company business management, Business, international
Abstract

Basel: Novartis has issued the following press release: Collaboration with Versant Ventures creates Borealis Biosciences, which will focus on discovering next-generation xRNA medicines for kidney diseases Novartis has option to [...]

Published
2024

3. Slope Spearheads Launch of Biospecimen Management Consortium to Drive Sample Excellence in Clinical Research

Subjects
Novartis AG -- Management, Medical research, Medicine, Experimental, Consortia, Clinical trials, Pharmaceutical industry, Consortium, Company business management, Business, News, opinion and commentary
Abstract

GRAIL, GSK, ILiAD, Moderna, Novartis, Roche, Takeda, and Teal Health join as founding members RICHMOND, Va., June 25, 2024 /PRNewswire/ -- Slope is excited to announce today the formation of [...]

Published
2024

4. Luqiao Group held an exchange meeting with the Chengdu Hi-tech Zone Management Committee

Subjects
Pfizer Inc. -- Management, Novartis AG -- Management, Pharmaceutical industry, Company business management, Business, Business, international
Abstract

Key Highlights: * Trinity Life Sciences is a leader in strategy, insights, and analytics for the life sciences industry * Nancy Phelan is the Senior Vice President and Head of [...]

Published
2024

5. Prevent Blindness to Host the 2024 ASPECT Patient Engagement and Advocacy Summit in Washington, D.C

Subjects
Johnson & Johnson -- Management, Novartis AG -- Management, Mallinckrodt PLC -- Management, Pharmaceutical industry, Company business management, Business, News, opinion and commentary
Abstract

Three-day event brings together patients, care partners, and public health champions to advance the goals of the Prevent Blindness ASPECT (Advocacy, Support, Perspective, Empowerment, Communication, and Training) Patient Engagement Program [...]

Published
2024

6. Deepening the Partnership: Dawn Health Introduces Ekiva for Enhanced Disease Management of Paroxysmal Nocturnal Hemoglobinuria (PNH)

Subjects
Novartis AG -- Management, Pharmaceutical industry, Company business management, General interest, News, opinion and commentary
Abstract

COPENHAGEN: Dawn Health Dawn Health has issued the following news release: Building upon their partnership announced last year, digital health leader Dawn Health and global pharmaceutical company Novartis are proud [...]

Published
2024

7. Deepening the Partnership : Dawn Health Introduces Ekiva for Enhanced Disease Management of Paroxysmal Nocturnal Hemoglobinuria (PNH)

Subjects
Novartis AG -- Management, Pharmaceutical industry, Company business management, General interest, News, opinion and commentary
Abstract

COPENHAGEN: Dawn Health has issued the following news release: Building upon their partnership announced last year, digital health leader Dawn Health and global pharmaceutical company Novartis are proud to announce [...]

Published
2024

8. Deepening the Partnership: Dawn Health Introduces Ekiva for Enhanced Disease Management of Paroxysmal Nocturnal Hemoglobinuria (PNH)

Subjects
Novartis AG -- Management, Pharmaceutical industry, Company business management, Business, News, opinion and commentary
Abstract

COPENHAGEN, Denmark, April 8, 2024 /PRNewswire/ -- Building upon their partnership announced last year, digital health leaderDawn Health and global pharmaceutical companyNovartis are proud to announce the launch ofEkiva PNH [...]

Published
2024

10. POINT Biopharma Global Inc at Bloom Burton & Co Healthcare Investor Conference - Final

Subjects
Novartis AG -- Management, Biological products industry, Health care industry, Pharmaceutical industry, Health care industry, Company business management, Business
Abstract

Presentation JAMES TRAN, ANALYST, BLOOM BURTON & CO.: Good afternoon, everyone. Our next presentation is from POINT Biopharma. Joining us today is Joe McCann, CEO. After the presentation, there'll be [...]

Published
2023

11. Novartis unveils new focused strategy, underpinned by eight potential multi-billion dollar peak sales brands & deep pipeline, at Meet the Management event

Subjects
Novartis AG -- Management, Company business management, Pharmaceuticals and cosmetics industries
Abstract

Novartis executives met the investors and industry analysts in Basel, sharing insights into the updated company strategy at the annual Meet Novartis Management event. The meeting will allow participants to [...]

Published
2022

12. Study Data from Humboldt University of Berlin Update Knowledge of Urticaria [Cruse®-an Innovative Mobile Application for Patient Monitoring and Management In Chronic Spontaneous Urticaria]

Subjects
Novartis AG -- Management, Mobile devices -- Research, Medical research, Medicine, Experimental, Wireless telephone software -- Research, Urticaria -- Research, Patient monitoring equipment -- Research, Pharmaceutical industry -- Research, Company business management, Health, Humboldt University of Berlin -- Management
Abstract

2024 FEB 9 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- New research on Skin Diseases and Conditions - Urticaria is the subject of [...]

Published
2024

13. Meet Novartis AG Management Investor Event - Final

Subjects
UBS Investment Bank -- Management, Novartis AG -- Management, Bank of America Corp. -- Management, Novartis International AG -- Management, Societe Generale S.A. -- Management, Company business management, Business, Pluvicto (Medication), Cosentyx (Medication), Entresto (Medication), Zolgensma (Medication), Gilenya (Medication), Kisqali (Medication)
Abstract

Presentation SAMIR SHAH, GLOBAL HEAD OF IR, NOVARTIS AG: So thank you, everybody. Really appreciate you taking the time to come here to Basel. I know some of you have [...]

Published
2022

14. New Data from Medical University Sofia Illuminate Findings in Breast Cancer (Management Strategies for Hyperglycemia Associated With the Alpha-selective Pi3k Inhibitor Alpelisib for the Treatment of Breast Cancer)

Subjects
Novartis AG -- Management, Women -- Health aspects, Strategic planning (Business) -- Analysis -- Research, Breast cancer -- Research -- Drug therapy, Hyperglycemia -- Drug therapy -- Research, Pharmaceutical industry -- Research -- Analysis, Company business management, Health, Women's issues/gender studies
Abstract

2022 MAY 19 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Current study results on Oncology - Breast Cancer have been published. According to news [...]

Published
2022

15. Data from Medical University of Sofia Broaden Understanding of Breast Cancer (Management Strategies for Hyperglycemia Associated with the a-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer)

Subjects
Novartis AG -- Management, Women -- Health aspects, Strategic planning (Business), Breast cancer -- Development and progression -- Drug therapy, Hyperglycemia -- Drug therapy -- Development and progression, Pharmaceutical industry, Company business management, Health, Women's issues/gender studies
Abstract

2022 APR 28 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Researchers detail new data in breast cancer. According to news originating from Sofia, Bulgaria, [...]

Published
2022

16. ARTBIO Launched to Develop New Class of Alpha Radioligand Therapies Designed to Maximize Therapeutic Potential

Subjects
Novartis AG -- Management, Pharmaceutical industry, Company business management, General interest, News, opinion and commentary
Abstract

CAMBRIDGE: ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ART), announced its founding with a $23 million seed financing led by F-Prime [...]

Published
2023

17. APQC Recognizes Eight Organizations for Excellence in Knowledge Management

Subjects
Novartis AG -- Management, Eni S.p.A. -- Management, Petroleum industry, Knowledge management, Pharmaceutical industry, Company business management, Knowledge management, General interest, News, opinion and commentary
Abstract

HOUSTON: APQC has issued the following news release: APQC, the benchmarking and best practices research firm, has named eight organizations as recipients of its 2023 Excellence in Knowledge Management (KM) [...]

Published
2023

18. APQC Recognizes Eight Organizations for Excellence in Knowledge Management

Subjects
Novartis AG -- Management, Eni S.p.A. -- Management, Petroleum industry, Knowledge management, Pharmaceutical industry, Company business management, Knowledge management, Business, Business, international
Abstract

HOUSTON -- APQC, the benchmarking and best practices research firm, has named eight organizations as recipients of its 2023 Excellence in Knowledge Management (KM) program. This year marks the fifth [...]

Published
2023

19. Mediar Therapeutics Announces $105 Million Financing to Advance Portfolio of First-in-Class Fibrosis Therapies

Subjects
Novartis AG -- Management, Eli Lilly and Co. -- Management, Sofinnova Partners -- Management, Fibrosis, Venture capital, Venture capital companies, Pharmaceutical industry, Company business management, Venture capital, General interest, News, opinion and commentary
Abstract

CAMBRIDGE: Mediar Therapeutics has issued the following news release: Mediar Therapeutics Inc., a biotechnology company advancing a portfolio of first-in-class therapies that halt and even reverse the course of fibrosis, [...]

Published
2023

20. Managing Risks for Cell and Gene Therapy Logistics: Vein-to-vein programmes are focusing on data access and traceability

Author

Shanley, Agnes

Subjects
Novartis AG -- Management, Contract manufacturing, Genes, Gene therapy, Logistics, Pharmaceutical industry, Company business management, Business, Pharmaceuticals and cosmetics industries
Abstract

The past few years have seen dramatic growth in cell and gene therapy research and commercializatio Developers are adding new laboratory and manufacturing capacity to help keep up with explosive [...]

Published
2020

21. Managing Risk for Cell and Gene Therapy Logistics: Vein-to-vein programs are focusing on data access and traceability

Author

Shanley, Agnes

Subjects
Novartis AG -- Management, Contract manufacturing, Risk management, Gene therapy, Genes, Pharmaceutical industry, Business logistics, Production management, Automation, Company business management, Risk management, Biotechnology industry, Business, Pharmaceuticals and cosmetics industries
Abstract

The past few years have seen dramatic growth in cell and gene therapy research and commercialization. Over the past few months, Kite Pharma and Novartis have both built new facilities [...]

Published
2020

22. Novartis inks pact with NHS to pioneer population health management approach to address elevated LDL-C in eligible patients with ASCVD across England

Subjects
Novartis AG -- Management, Statins, Management techniques, Management, Cardiovascular diseases -- Care and treatment, Cardiac patients -- Care and treatment, Low density lipoproteins, Pharmaceutical industry, Company business management, Pharmaceuticals and cosmetics industries
Abstract

Novartis has reached a commercial agreement with the NHS in England as part of collaboration to pioneer a first-of-its-kind population health management approach to address elevated LDL-C in eligible patients [...]

Published
2021

23. Novartis Ag Files SEC Form DFAN14A, Additional Definitive Proxy Soliciting Materials Filed By Non-management And Rule 14(A)(12) Material: (Jul. 10, 2023)

Subjects
United States. Securities and Exchange Commission -- Management, Novartis AG -- Management, Securities law, Proxy, Pharmaceutical industry, Company business management, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2023 JUL 24 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2023

24. Novartis Ag Files SEC Form DFAN14A, Additional Definitive Proxy Soliciting Materials Filed By Non-management And Rule 14(A)(12) Material: (Jun. 12, 2023)

Subjects
United States. Securities and Exchange Commission -- Management, Novartis AG -- Management, Securities law, Proxy, Pharmaceutical industry, Company business management, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2023 JUN 26 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2023

25. APQC Recognizes Eight Organizations for Excellence in Knowledge Management

Subjects
Novartis AG -- Management, Eni S.p.A. -- Management, Petroleum industry, Knowledge management, Pharmaceutical industry, Company business management, Knowledge management, Computers
Abstract

2023 JUN 20 (VerticalNews) -- By a News Reporter-Staff News Editor at Information Technology Newsweekly -- APQC, the benchmarking and best practices research firm, has named eight organizations as recipients [...]

Published
2023

26. Studies from Novartis Reveal New Findings on Gene Therapy (Inherited Retinal Diseases Due to * * RPE65* * Variants: From Genetic Diagnostic Management to Therapy)

Subjects
Novartis AG -- Management, Genetic research -- Genetic aspects, Genes -- Research -- Genetic aspects, Retinal diseases -- Genetic aspects -- Research, Physical fitness -- Research, Pharmaceutical industry -- Research, Company business management, Health
Abstract

2021 AUG 7 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on gene therapy have been presented. According to news reporting [...]

Published
2021

27. Western companies to play key role in improving cardiovascular disease management approach in China, says GlobalData

Subjects
Bayer AG -- Management, Novartis AG -- Management, Management techniques, Management, Drug approval, Cardiovascular diseases, Pharmaceutical industry, Company business management, Business, Chemicals, plastics and rubber industries
Abstract

Cardiovascular diseases (CVDs) continue to be the leading cause of death globally, with China being no exception. As domestic companies are mostly involved in providing generic drugs for CVDs, China is heavily reliant on foreign players. Against this backdrop, key foreign players will play a crucial role in improving the overall CVD management approach in China, says GlobalData, a leading data and analytics company. Key players in China's CVD market like Novartis and Bayer are adopting various strategic approaches, including enhancing their research and development and manufacturing capabilities, and novel drugs launch. As a strategy to expedite the local approval process for its innovative therapies, Novartis is conducting a geography-specific clinical trial for Leqvio (inclisiran), through which it is assessing the real-world effectiveness of the drug in Chinese patients with primary hypercholesterolemia or mixed dyslipidaemia (NCT05118230). Leqvio, being the first and only small interfering RNA therapy approved in over 60 countries globally for the treatment of hypercholesterolemia, is expected to address the key issue associated with CVD management in China, ie, the need for better adherence to therapy, as Leqvio is injected only twice a year. Bayer's Verquvo (vericiguat) was approved in China for the treatment of patients with chronic heart failure and reduced ejection fraction in May 2022. Original source: Global Data, website: http://www.energy.globaldata.com, Copyright Global Data 2023., research and development; biological therapeutics; cardiovascular drugs; generic pharmaceuticals; inclisiran; Leqvio; ribonucleic acids; vericiguat; Verquvo; Bayer; [...]

Published
2023

28. Task force on management and prevention of Acinetobacter baumannii infections in the ICU

Author

Garnacho-Montero, José, Dimopoulos, George, Poulakou, Garyphallia, Akova, Murat, Cisneros, José Miguel, De Waele, Jan, and Petrosillo, Nicola

Subjects
Astellas Pharma Inc. -- Management, Johnson & Johnson -- Management, Pfizer Inc. -- Management, Gilead Sciences Inc. -- Management, Novartis AG -- Management, Task forces -- Usage -- Health aspects, Communicable diseases -- Prevention -- Care and treatment, Hygiene -- Usage -- Health aspects, Infection -- Care and treatment -- Prevention, Medical colleges -- Health aspects -- Usage, Antibiotics -- Usage, Medical laboratories -- Health aspects -- Usage, Septic shock -- Care and treatment -- Prevention, Company business management, Health care industry
Abstract

Introduction Acinetobacterbaumannii constitutes a dreadful problem in many ICUs worldwide. The very limited therapeutic options available for these organisms are a matter of great concern. No specific guidelines exist addressing the prevention and management of A. baumannii infections in the critical care setting. Methods Clinical microbiologists, infectious disease specialists and intensive care physicians were invited by the Chair of the Infection Section of the ESICM to participate in a multidisciplinary expert panel. After the selection of clinically relevant questions, this document provides recommendations about the use of microbiological techniques for identification of A. baumannii in clinical laboratories, antibiotic therapy for severe infections and recommendations to control this pathogen in outbreaks and endemic situations. Evidence supporting each statement was graded according to the European Society of Clinical Microbiology and Infection Diseases (ESCMID) grading system. Results Empirical coverage of A. baumannii is recommended in severe infections (severe sepsis or septic shock) occurring during an A. baumannii outbreak, in an endemic setting, or in a previously colonized patient. For these cases, a polymyxin is suggested as part of the empirical treatment in cases of a high suspicion of a carbapenem-resistant (CR) A. baumannii strain. An institutional program including staff education, promotion of hand hygiene, strict contact and isolation precautions, environmental cleaning, targeted active surveillance, and antimicrobial stewardship should be instituted and maintained to combat outbreaks and endemic situations. Conclusions Specific recommendations about prevention and management of A. baumannii infections in the ICU were elaborated by this multidisciplinary panel. The paucity of randomized controlled trials is noteworthy, so these recommendations are mainly based on observational studies and pharmacodynamics modeling., Author(s): José Garnacho-Montero [sup.1], George Dimopoulos [sup.2], Garyphallia Poulakou [sup.3], Murat Akova [sup.4], José Miguel Cisneros [sup.5], Jan De Waele [sup.6], Nicola Petrosillo [sup.7], Harald Seifert [sup.8] [sup.9], Jean François [...]

Published
2015
Full Text
View/download PDF

29. New Findings in Male Kidney Diseases and Conditions Described from German Heart Center Berlin (Cardiac Surgery - Related Acute Kidney Injury _ Risk Factors, Clinical Course, Management Suggestions)

Subjects
Novartis AG -- Management, Abbott Laboratories (Abbott Park, Illinois) -- Management, Boston Scientific Corp. -- Management, Medical research -- Health aspects, Medicine, Experimental -- Health aspects, Medical test kit industry -- Research -- Health aspects, Medical equipment and supplies industry -- Research -- Health aspects, Kidney diseases -- Risk factors -- Research, Pharmaceutical industry -- Health aspects -- Research, Company business management, Health
Abstract

2023 FEB 27 (NewsRx) -- By a News Reporter-Staff News Editor at Cardiovascular Week -- Investigators discuss new findings in Kidney Diseases and Conditions - Male Kidney Diseases and Conditions. [...]

Published
2023

30. Findings from Department of Medicine Advance Knowledge in Neuroendocrine Cancer (Evaluation of quality of clinical management of neuroendocrine tumors) (Evaluation of quality of clinical management of neuroendocrine tumors)

Subjects
Novartis AG -- Management, Cancer -- Drug therapy, Medical imaging equipment -- Research, Evidence-based medicine -- Research, Pharmaceutical industry -- Research, Company business management, Health, Law
Abstract

2023 JAN 3 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Imaging Law Weekly -- Investigators discuss new findings in neuroendocrine cancer. According to news reporting from the [...]

Published
2023

31. Sprout Social blossoms as a public company; Why investors love this money-losing software maker

Subjects
Novartis AG -- Management, Publicly held corporations, Computer software industry, Social media, Pharmaceutical industry, Company business management, Business, Business, regional
Abstract

Byline: John Pletz Sprout Social is off to a better start than any other Chicago startup that has gone public in the past decade. At just over $131 per share [...]

Published
2021

32. Interim Management Statement Q1 2022 of Molecular Partners: Cash Runway into 2026 and Portfolio Progress Highlight Strategic Momentum

Subjects
United States. Food and Drug Administration -- Management, Novartis AG -- Management, Homeopathy -- Materia medica and therapeutics, Biotechnology industry, Corporations -- Finance, Therapeutics, Pharmaceutical industry, Company business management, Banking, finance and accounting industries, Business
Abstract

ZURICH-SCHLIEREN, Switzerland and CONCORD, May 12, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NASDAQ:MOLN),(SWX:MOLN.SW), EQNX::TICKER_END Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), [...]

Published
2022

33. United States : MPAACT Consortium Unites Industry and Academia to Establish Measurable Residual Disease as a Surrogate Endpoint in Acute Myeloid Leukemia Drug Development

Subjects
Johnson & Johnson -- Management, Novartis AG -- Management, Roche Holding AG -- Management, Celgene Corp. -- Management, Oncology, Experimental, Antineoplastic agents, Biotechnology industry, Cancer -- Research, Pharmaceutical industry, Antimitotic agents, Company business management, Business, international
Abstract

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the Measurable residual disease Partnership and Alliance in Acute myeloid leukemia Clinical Treatment (MPAACT), an industry-led research alliance founded in 2018 [...]

Published
2022

34. MPAACT Consortium Unites Industry and Academia to Establish Measurable Residual Disease as a Surrogate Endpoint in Acute Myeloid Leukemia Drug Development

Subjects
Johnson & Johnson -- Management, Novartis AG -- Management, Roche Holding AG -- Management, Celgene Corp. -- Management, Oncology, Experimental, Antineoplastic agents, Biotechnology industry, Cancer -- Research, Pharmaceutical industry, Antimitotic agents, Company business management, General interest, News, opinion and commentary
Abstract

New Brunswick, New Jersey: Johnson & Johnson has issued the following press release: The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the Measurable residual disease Partnership and Alliance [...]

Published
2022

35. FORE School of Management strikes 100 % placement with highest Package at 41 LPA

Subjects
Novartis AG -- Management, HDFC Bank Ltd. -- Management, Business schools, Banking industry, Pharmaceutical industry, Company business management, Banking industry, Telecommunications industry
Abstract

New Delhi-based, FORE School of Management achieved 100 percent placement for the current batch of 2020-22. The Institute engages the Industry by inviting them to the campus for Final Placements, [...]

Published
2022

36. Data on Heart Failure Discussed by Researchers at King Saud University [Saudi Heart Association (SHA) guidelines for the management of heart failure]

Subjects
Novartis AG -- Management, Heart failure, Physical fitness, Pharmaceutical industry, Associations, Mortality, Morbidity, Obesity, Medical economics, Health care costs, Editors, Company business management, Health, King Saud University -- Management
Abstract

2019 NOV 2 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on heart failure. According to news originating from [...]

Published
2019

37. Researchers at University of Paris Diderot Target Kaposi Sarcoma (Management of Kaposi sarcoma after solid organ transplantation: A European retrospective study)

Subjects
Novartis AG -- Management, Kaposi's sarcoma -- Research -- Care and treatment, Physical fitness, Skin diseases -- Research -- Care and treatment, Chemotherapy, Medical research, Immunotherapy, Organ transplantation, Pharmaceutical industry, Obesity, Cancer treatment, Skin, Sarcoma, Editors, Company business management, Health
Abstract

2019 JUL 13 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Skin Diseases and Conditions - Kaposi Sarcoma have [...]

Published
2019

38. Sheldon Gross Realty brokers sale of 5,000-square-foot flex space in Milburn

Subjects
Novartis AG -- Management, Real estate agents and brokers, Pharmaceutical industry, Real property, Company business management, Business, regional
Abstract

Byline: Linda Lindner Advanced Accelerator Applications, a Novartis company, on May 25 announced it expanded its footprint in Millburn by purchasing 45 E. Willow St., a 5,000-square-foot flex space adjacent [...]

Published
2021

39. Aktana and Cantab Pi Bring Together 2M+ Data Sets and Predictive Analytics at Scale to Optimize HCP Engagement

Subjects
Novartis AG -- Management, Artificial intelligence, Machine learning, Company business management, Artificial intelligence, Business, Business, international
Abstract

Novartis first to pilot Aktana / Cantab Pi combined analytics platform SAN FRANCISCO & CAMBRIDGE, England -- Aktana, the leader in intelligent customer engagement for the global life sciences industry, [...]

Published
2021

40. Versanis Bio Announces $70 Million Series A Financing to Advance Bimagrumab for the Treatment of Obesity

Subjects
Novartis AG -- Management, Atlas Venture -- Management, Obesity -- Care and treatment, Venture capital companies, Pharmaceutical industry, Company business management, Business, international, Law
Abstract

Versanis Bio today announced the closing of its Series A financing of $70 million to advance the clinical development of bimagrumab, an activin receptor type II antagonist. The company was [...]

Published
2021

41. Versanis Bio Announces $70 Million Series A Financing to Advance Bimagrumab for the Treatment of Obesity

Subjects
Novartis AG -- Management, Atlas Venture -- Management, Obesity -- Care and treatment, Venture capital companies, Pharmaceutical industry, Company business management, General interest, News, opinion and commentary
Abstract

OAKLAND: VERSANIS BIO has issued the following news release: Versanis Bio today announced the closing of its Series A financing of $70 million to advance the clinical development of bimagrumab, [...]

Published
2021

42. MPAACT Consortium Unites Industry and Academia to Establish Measurable Residual Disease as a Surrogate Endpoint in Acute Myeloid Leukemia Drug Development

Subjects
Johnson & Johnson -- Management, Novartis AG -- Management, Roche Holding AG -- Management, Celgene Corp. -- Management, Oncology, Experimental, Antineoplastic agents, Biotechnology industry, Cancer -- Research, Pharmaceutical industry, Antimitotic agents, Company business management, Business, Health, Health care industry
Abstract

2022 MAY 17 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced the Measurable residual disease Partnership and [...]

Published
2022

43. Versanis Bio Announces $70 Million Series A Financing to Advance Bimagrumab for the Treatment of Obesity

Subjects
Novartis AG -- Management, Atlas Venture -- Management, Obesity -- Care and treatment, Investment companies, Venture capital companies, Pharmaceutical industry, Company business management, Business, Business, international
Abstract

Leading life science investors Atlas Venture and Medicxi led the financing with participation from founding investor Aditum Bio OAKLAND, Calif. -- Versanis Bio today announced the closing of its Series [...]

Published
2021

44. Replica Analytics Adds Bench Strength To Its Health Technology Brain Trust

Subjects
Novartis AG -- Management, Medical research, Medicine, Experimental, High technology industry, Pharmaceutical industry, Company business management, Business, international, Law
Abstract

Replica Analytics announced today the formation of an Advisory Board and its first three members. The three new members have extensive experience in health research, data analysis, data sharing, and [...]

Published
2021

45. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

Author

Nathan, David M., Buse, John B., Davidson, Mayer B., Ferrannini, Ele, Holman, Rury R., Sherwin, Robert, and Zinman, Bernard

Subjects
Merck & Company Inc. -- Management, Pfizer Inc. -- Management, Novartis AG -- Management, Eli Lilly and Co. -- Management, Diabetes therapy, Thiazolidinediones, Type 2 diabetes -- Development and progression -- Care and treatment, Hyperglycemia -- Development and progression -- Care and treatment, Algorithms, Pharmaceutical industry, Company business management, Algorithm, Health, American Diabetes Association -- Management
Abstract

The consensus algorithm for the medical management of type 2 diabetes was published in August 2006 with the expectation that it would be updated, based on the availability of new [...]

Published
2009

46. LATEST COMPANY NEWS

Subjects
United States. Food and Drug Administration -- Management, United States. Supreme Court -- Management, BioNTech SE -- Management, Pfizer Inc. -- Management, Viatris Inc. -- Management, Mylan N.V. -- Management, Novartis AG -- Management, GlaxoSmithKline PLC -- Management, AstraZeneca PLC -- Management, Eisai Company Ltd. -- Management, Biotechnology industry, Monoclonal antibodies, Pharmaceutical industry, Company business management, Business, international, European Union -- Management, Comirnaty (Vaccine), Xeljanz (Medication), Ibrance (Medication), Advair Diskus (Medication), Chantix (Medication)
Abstract

Daily Echo - New trial of Covid-19 drug launches in Southampton - 8/1/2022 A new trial of a 'game-changing' pill to combat Covid-19 has opened in Southampton. For the complete [...]

Published
2022

47. Interim Management Statement Q1 2021: Major Advances in COVID-19 Program, Continued Progress in Oncology Pipeline

Subjects
Novartis AG -- Management, Biotechnology industry, Pharmaceutical industry, Company business management, General interest, News, opinion and commentary
Abstract

ZURICH-SCHLIEREN: Molecular Partners AG has issued the following news release: Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin(r) therapeutics, [...]

Published
2021

48. New Spherix Global Insights' Patient Audit Highlights Key Differences Between Dermatologists' and Rheumatologists' Management of Psoriatic Arthritis, Focusing on Patients Recently Switched Between Advanced Systemic Treatment Brands

Subjects
Novartis AG -- Management, Eli Lilly and Co. -- Management, Psoriatic arthritis -- Drug therapy, Dermatology -- Formulae, receipts, prescriptions, Drug approval, Skin, Dermatologic agents, Brand name products, Pharmaceutical industry, Company business management, General interest, News, opinion and commentary, Cosentyx (Medication), Taltz (Medication), Tremfya (Medication)
Abstract

EXTON: Spherix Global Insights has issued the following news release: The past five or so years have seen a flurry of US biologic approvals for the treatment of psoriasis (PSO), [...]

Published
2021

49. New Spherix Global Insights' Patient Audit Highlights Key Differences Between Dermatologists' and Rheumatologists' Management of Psoriatic Arthritis, Focusing on Patients Recently Switched Between Advanced Systemic Treatment Brands

Subjects
Novartis AG -- Management, Eli Lilly and Co. -- Management, Psoriatic arthritis -- Care and treatment, Dermatology -- Formulae, receipts, prescriptions, Skin, Dermatologic agents, Brand name products, Pharmaceutical industry, Company business management, Business, News, opinion and commentary
Abstract

US dermatologists report increased confidence in treating psoriatic arthritis patients without a rheumatologist, and the two specialist groups report different drivers behind key treatment decisions in patient management EXTON, Pa., [...]

Published
2021

50. Aktis Oncology Announces $72M Series A Financing To Advance Breakthrough Radiopharmaceuticals To Treat Solid Tumors

Subjects
MPM Capital -- Management, Novartis AG -- Management, Tumors, Investment companies, Pharmaceutical industry, Company business management, General interest, News, opinion and commentary
Abstract

CAMBRIDGE: Aktis Oncology has issued the following news release: Aktis Oncology, a biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals to treat a broad range of solid [...]

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results